Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189


Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.

Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD Jr, Clark OH, Ruan DT.

J Clin Endocrinol Metab. 2011 Mar;96(3):E554-65. doi: 10.1210/jc.2010-1800. Epub 2010 Dec 29.


Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.

Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E.

Surgery. 2008 Dec;144(6):908-13; discussion 913-4. doi: 10.1016/j.surg.2008.07.028.


Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.

Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD Jr, Ruan DT.

Surgery. 2011 Dec;150(6):1295-302. doi: 10.1016/j.surg.2011.09.014.


Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.

Li Z, Qu L, Zhong H, Xu K, Qiu X, Wang E.

Oncol Rep. 2014 Apr;31(4):1707-14. doi: 10.3892/or.2014.3050. Epub 2014 Feb 24.


LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.

Zhao S, Wang Q, Li Z, Ma X, Wu L, Ji H, Qin G.

J Exp Clin Cancer Res. 2015 Dec 4;34:146. doi: 10.1186/s13046-015-0265-z.


Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.

Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A.

PLoS One. 2015 Jun 12;10(6):e0129859. doi: 10.1371/journal.pone.0129859. eCollection 2015.


Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.

Kunstman JW, Korah R, Healy JM, Prasad M, Carling T.

Surgery. 2013 Dec;154(6):1255-61; discussion 1261-2.


MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.

Zhang X, Li D, Li M, Ye M, Ding L, Cai H, Fu D, Lv Z.

Int J Cancer. 2014 Jan 15;134(2):257-67. doi: 10.1002/ijc.28141. Epub 2013 Sep 18.


The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.

Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.

Cancer Res. 2009 Nov 1;69(21):8317-25. doi: 10.1158/0008-5472.CAN-09-1248. Epub 2009 Oct 27.


Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.

Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M.

Int J Cancer. 2006 Nov 15;119(10):2322-9.


BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Xing M.

Endocr Rev. 2007 Dec;28(7):742-62. Epub 2007 Oct 16. Review.


Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.

Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, Zhou Y, Xing M.

Oncotarget. 2016 Feb 2;7(5):5830-41. doi: 10.18632/oncotarget.6709.


Downregulation of Mig-6 in nonsmall-cell lung cancer is associated with EGFR signaling.

Li Z, Dong Q, Wang Y, Qu L, Qiu X, Wang E.

Mol Carcinog. 2012 Jul;51(7):522-34. doi: 10.1002/mc.20815. Epub 2011 Jul 7.


BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.

Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA.

Endocrinology. 2006 Feb;147(2):1014-9. Epub 2005 Oct 27.


Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.

Feng C, Gao Y, Wang C, Yu X, Zhang W, Guan H, Shan Z, Teng W.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1524-33. doi: 10.1210/jc.2012-4258. Epub 2013 Jul 11.


The expression and role of serum response factor in papillary carcinoma of the thyroid.

Kim HJ, Kim KR, Park HS, Jang KY, Chung MJ, Shong M, Moon WS.

Int J Oncol. 2009 Jul;35(1):49-55.


Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.

Degl'Innocenti D, Alberti C, Castellano G, Greco A, Miranda C, Pierotti MA, Seregni E, Borrello MG, Canevari S, Tomassetti A.

PLoS One. 2010 Sep 22;5(9):e12701. doi: 10.1371/journal.pone.0012701.


Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma.

Reschke M, Ferby I, Stepniak E, Seitzer N, Horst D, Wagner EF, Ullrich A.

Hepatology. 2010 Apr;51(4):1383-90. doi: 10.1002/hep.23428.


Aberrant expression of COT is related to recurrence of papillary thyroid cancer.

Lee J, Jeong S, Park JH, Lee CR, Ku CR, Kang SW, Jeong JJ, Nam KH, Shin DY, Lee EJ, Chung WY, Jo YS.

Medicine (Baltimore). 2015 Feb;94(6):e548. doi: 10.1097/MD.0000000000000548.


Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.

Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O.

Pathol Int. 2005 Dec;55(12):757-65.


Supplemental Content

Support Center